Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410384 · ClinicalTrials.gov registry record · Phase 3
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 819
- Enrollment target
- 20
- Study locations
NCT00410384 is a Phase 3 study of Systemic Lupus Erythematosus that has completed, run by Human Genome Sciences. The registered enrollment target is 819 participants, above the 372-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00410384, a Phase 3 study of Systemic Lupus Erythematosus, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 819 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Belimumab 1 mg/kg
- DRUG Belimumab 10 mg/kg
Study Locations (20)
California
- Talbert Medical Group - Huntington Beach
- Valerius Medical Group & Research Ctr of Greater Long Beach, Inc. - Long Beach
- University of Southern California - Los Angeles
- Wallace Rheumatic Study Center - Los Angeles
- UCLA Rheumatology - Los Angeles
- Arthritis Care Center, Inc. - San Jose
- Inland Rheumatic Disease Specialties - Upland
Florida
- Arthritis and Rheumatic Disease Specialties - Aventura
- University of Miami-Division of Rheumatology and Immunology - Miami
- Rheumatology Associates of Central Florida - Orlando
- Southwest Florida Clinical Research Center - Tampa
- Tampa Medical Group, P.A. - Tampa
Arizona
- Arizona Arthritis and Rheumatology Research, PPLC - Paradise Valley
- The University of Arizona Arthritis Center - Tucson
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Arthritis Associates of Colorado Springs - Colorado Springs
District of Columbia
- Washington Hospital Center - Washington D.C.
Georgia
- Emory University - Atlanta
Idaho
- Selah Medical Clinical Research Unit - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 819 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410384
The ClinicalTrials.gov registry entry for NCT00410384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 819 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 372-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (120% higher). The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00410384 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00410384 about?
NCT00410384 is a clinical study titled "A Study of Belimumab in Subjects With Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
What is the current status of trial NCT00410384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 819 participants. The study started on 2006-12. Estimated completion is 2010-03.
What conditions does trial NCT00410384 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00410384?
The interventions under investigation include: Placebo (DRUG), Belimumab 1 mg/kg (DRUG), Belimumab 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00410384?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00410384 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.